miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 18, 2026

5 Financial Transaction Stocks to Watch Despite Elevated Expense Level

View original at finance.yahoo.com
5 Financial Transaction Stocks to Watch Despite Elevated Expense Level The Financial Transaction Services industry is likely to benefit from expanding global trade, rising international travel and growing demand for seamless cross-border payments and remittances…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fidelity National's earnings beat estimates in three of the last four quarters and matched once, with average surprise of 1.64%

    80% confidence

  • Mastercard's earnings beat estimates in each of the last four quarters, with an average surprise of 5.48%

    80% confidence

  • Mastercard carries a Zacks Rank #3 (Hold)

    80% confidence

  • Zacks Consensus Estimate for Mastercard's 2026 earnings is $19.38 per share, indicating a 13.9% rise from the year-ago figure

    80% confidence

  • Persistent inflation and tariff pressures may further strain consumer budgets in the financial transaction services space

    80% confidence

  • Zacks Consensus Estimate for Fidelity National's 2026 earnings is $6.27 per share, indicating an improvement of 8.7% from the 2025 estimate

    80% confidence

  • Global Payments' earnings beat estimates in three of the last four quarters and missed once, with an average surprise of 1.93%

    80% confidence

  • The Financial Transaction Services industry is likely to benefit from expanding global trade, rising international travel and growing demand for seamless cross-border payments and remittances

    80% confidence

  • The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one

    80% confidence

  • Visa's earnings beat estimates in each of the last four quarters, with an average surprise of 2.12%

    80% confidence

  • The Financial Transaction Services industry has declined 24.3% compared with the Business Services sector's decline of 24.4% over the past year

    80% confidence

  • The Financial Transaction Services industry is currently trading at a forward 12-month P/E of 18.15X, compared with the S&P 500's 22.51X and the sector's 18X

    80% confidence

  • Fiserv carries a Zacks Rank #3 (Hold)

    80% confidence

  • Fiserv's earnings beat estimates in three of the last four quarters and missed once

    80% confidence

  • Global Payments carries a Zacks Rank #2 (Buy)

    80% confidence

  • Fidelity National carries a Zacks Rank #3 (Hold)

    80% confidence

  • With expectations for interest rate cuts in 2026, companies may increasingly use debt financing to fund acquisitions and accelerate growth

    80% confidence

  • Zacks Consensus Estimate for Global Payments' 2026 earnings is $13.85 per share, indicating a 13.3% rise from the 2025 estimate

    80% confidence

  • Zacks Consensus Estimate for Fiserv's 2026 earnings is $8.14 per share, with revenue consensus implying 3.4% improvement from year-ago

    80% confidence

  • Visa carries a Zacks Rank #3 (Hold)

    80% confidence

  • In the past five years, the Financial Transaction Services industry traded as high as 36.92X, as low as 18.15X and at the median of 22.24X on a forward P/E basis

    80% confidence

  • Zacks Consensus Estimate for Visa's fiscal 2026 earnings is $12.84 per share, indicating an 11.9% rise from the year-ago figure

    80% confidence

  • The Zacks Financial Transaction Services industry currently carries a Zacks Industry Rank #135, placing it in the bottom 44% of 243 Zacks industries

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
5 Financial Transaction Stocks to Watch Despite Elevated Expense Level — Source | Via News | es.VIA.NEWS